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Background: NaV1.7 is preferentially expressed, at relatively high levels, in peripheral neurons, and is often referred
to as a “peripheral” sodium channel, and NaV1.7-specific blockers are under study as potential pain therapeutics
which might be expected to have minimal CNS side effects. However, occasional reports of patients with NaV1.7
gain-of-function mutations and apparent hypothalamic dysfunction have appeared. The two sodium channels
previously studied within the rat hypothalamic supraoptic nucleus, NaV1.2 and NaV1.6, display up-regulated
expression in response to osmotic stress.
Results: Here we show that NaV1.7 is present within vasopressin-producing neurons and oxytocin-producing
neurons within the rat hypothalamus, and demonstrate that the level of Nav1.7 immunoreactivity is increased in
these cells in response to osmotic stress.
Conclusions: NaV1.7 is present within neurosecretory neurons of rat supraoptic nucleus, where the level of
immunoreactivity is dynamic, increasing in response to osmotic stress. Whether NaV1.7 levels are up-regulated
within the human hypothalamus in response to environmental factors or stress, and whether NaV1.7 plays a
functional role in human hypothalamus, is not yet known. Until these questions are resolved, the present findings
suggest the need for careful assessment of hypothalamic function in patients with NaV1.7 mutations, especially
when subjected to stress, and for monitoring of hypothalamic function as NaV1.7 blocking agents are studied.
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Gain-of-function mutations of the NaV1.7 sodium chan-
nel, which is preferentially expressed at relatively high
levels within peripheral (dorsal root ganglion and sym-
pathetic ganglion) neurons [1-3] produce several syn-
dromes associated with severe pain, including inherited
erythromelalgia [4-8] and paroxysmal extreme pain dis-
order [9,10] as well as painful small-fiber neuropathy
[11,12], while loss-of-function mutations of NaV1.7 cause
channelopathy-associated insensitivity to pain [13-15]. In
contrast with the severe pain associated with gain-of-* Correspondence: stephen.waxman@yale.edu
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reproduction in any medium, provided the orfunction mutations of NaV1.7 and loss of pain sensitivity
associated with loss-of-function mutations of NaV1.7, ab-
normalities of CNS function have in general not been
reported in these disorders, consistent with preferential
expression of NaV1.7 within peripheral neurons. NaV1.7-
specific blockers are being studied as potential therapies
for pain, with the rationale that they would be expected
to have few, if any, CNS-related side-effects. Neverthe-
less, there have been reports of hypothermia, possibly
due to an abnormality of central (hypothalamic) thermo-
regulation [16-18] in patients with NaV1.7 mutations
and erythromelalgia. The syndrome of inappropriate re-
lease of antidiuretic hormone, SIADH, without any struc-
tural cause, recently developed in a patient carrying a
gain-of-function mutation of NaV1.7, G856D, within a kin-
dred with painful small-fiber neuropathy (Hoeijmakers et
al, personal communication). Affected family members, all
of whom carry the G856D mutation, display small-fiberd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Nav1.7 expression in vasopressin- and oxytocin-
producing magnocellular neurosecretory cells in supraoptic
nucleus. Magnocellular neurosecretory neurons (MSN) of the
supraoptic nucleus (SON) exhibit robust vasopressin and oxytocin
immunolabeling (green). MSN of the SON display Nav1.7 immuno-
reactivity (red). Double-immunocytochemical studies with antibodies
to vasopressin or oxytocin and Nav1.7 demonstrate that both
peptide-producing cell-types exhibit co-localization (magenta) with
Nav1.7. Merged image of vasopressin or oxytocin with Nav1.7 is
presented as magenta to enhance visualization of co-localization.
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dyscontrol in their distal extremities, small hands and feet,
and autonomic dysfunction. The G856D mutation en-
hances channel activation, impairs fast-inactivation, and
markedly enhances the channel’s persistent current and
response to slow ramp stimuli. The occurrence of SIADH
in this patient suggested the possibility that the gain-of
-function mutation in NaV1.7 might have contributed to
hyperexcitability of vasopressin-releasing (magnocellular
neurosecretory) neurons in the supraoptic nucleus within
the hypothalamus.
Vasopressin release by supraoptic magnocellular neu-
rons can be triggered by osmotic stress and depends on
bursting activity in these cells [19]. It is known that
tetrodotoxin-sensitive sodium channels contribute to
this bursting [20-22]. While high levels of expression of
NaV1.7 have been reported in hypothalamic nuclei in-
cluding the supraoptic nucleus in rodents [13,23], only
weak levels of NaV1.7 expression were detected within
the primate supraoptic nucleus [13]. In the present study,
we have built upon earlier studies in rodents which
showed that the deployment of sodium channels in the
hypothalamus is dynamic, with levels of expression of the
two sodium channel subtypes that were previously
studied, NaV1.2 and NaV1.6, and of sodium channel beta-1
and beta-2 subunits and sodium currents, displaying up-
regulation within supraoptic magnocellular neurons ex-
posed to osmotic stress via salt-loading [24] and as a result
of the hyperosmolar state associated with experimental
diabetes [25]. Reasoning that Nav1.7 expression within
supraoptic magnocellular neurons might be subject to
similar plasticity, we exposed rats to salt-loading and
assessed the level of NaV1.7 immunoreactivity within these
neurons. We demonstrate here that NaV1.7 is present
within vasopressin- and oxytocin-producing neurons of
the supraoptic nucleus, and show that the level of NaV1.7
protein in these cells in not static but, on the contrary, is
increased in response to salt-loading.
Results
Previous work from our laboratory has demonstrated
the expression of the tetrodotoxin-sensitive (TTX-S)
sodium channels, NaV1.2 and NaV1.6, but not NaV1.1
and NaV1.3, and of TTX-S sodium currents in magno-
cellular neurosecretory cells (MSC) of the hypothalamic
supraoptic nucleus [24]. This early study also showed
that the expression of NaV1.2 and NaV1.6 channels are
upregulated and amplitude of the sodium current
increased following salt-loading challenge [24]. To
determine whether NaV1.7 is expressed and upregu-
lated in magnocellular neurosecretory cells of the supra-
optic nucleus, we assessed the supraoptic nucleus of
control and salt-loaded (2% NaCl in drinking water) rats
using immunocytochemistry. Measurement of plasmaosmotic pressure confirmed the presence of hyperosmo-
larity in the salt-loaded rats: control, 323.3 ± 4.8 mOsm;
salt-loaded, 353.2 ± 3.3 mOsm (p < 0.05).
Magnocellular neurosecretory cells in the supraoptic
nucleus of control rats exhibited distinct NaV1.7
immunolabeling (Figure 1). Some magnocellular neuro-
secretory cells displayed moderate levels of NaV1.7
immunosignal, while other magnocellular neurosecretory
cells exhibited a low level or no NaV1.7 immunofluores-
cence. Two types of magnocellular neurosecretory cells
exist within the supraoptic nucleus, oxytocin-producing
and vasopressin-producing, with little co-expression of
these hormones in individual magnocellular neurosecre-
tory cells. Both oxytocin- and vasopressin-producing
magnocellular neurosecretory cells displayed NaV1.7
immunolabeling (Figure 1). Approximately 72% (33 of
46) of oxytocin-producing and 53% (59 of 112) of
vasopressin-producing MSC expressed NaV1.7 labeling
above background levels.
Salt-loading induced a substantial increase in the level
of NaV1.7 immunoreactivity in magnocellular neurose-
cretory cells of the supraoptic nucleus compared to
magnocellular neurosecretory cells in control rats
(Figure 2A). In addition to the detection of greater num-
bers of magnocellular neurosecretory cells that displayed
NaV1.7 immunolabeling, the intensity of NaV1.7 signal
Figure 2 Nav1.7 is upregulated in magnocellular
neurosecretory neurons of supraoptic nucleus following salt
loading. (A) Magnocellular neurosecretory neurons (MSN) within
supraoptic nucleus (SON) of control rats exhibit Nav1.7 immunolabe-
ling. Following salt-loading, MSN display more prominent Nav1.7
immunoreactivity compared to control rats. (B) Quantification of
Nav1.7 immunosignal within the SON demonstrates an approximate-
ly two-fold increase in Nav1.7 immunofluorescence in SON of salt-
loaded rats compared to control rats.
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markedly greater than that observed in magnocellular
neurosecretory cells from control rats. Quantification
of the mean intensity of NaV1.7 signal within the
circumscribed supraoptic nucleus demonstrated a signifi-
cant up regulation of NaV1.7 in response to salt-loading
challenge (Figure 2B). These observations demonstrate
that, in addition to up regulation of the TTX-S sodium
channels NaV1.2 and NaV1.6 within magnocellular neuro-
secretory cells of the supraoptic nucleus with salt-loading,
the level of NaV1.7 protein in these cells is significantly
increased in osmotically-challenged rats.Discussion
In this study we have demonstrated that NaV1.7 is
present within neurons within the hypothalamic supra-
optic nucleus, specifically within vasopressin- and
oxytocin-producing magnocellular neurosecretory neu-
rons. We also show that the level of NaV1.7 protein in
these cells is not fixed but, on the contrary, is dynamic,
increasing as a result of salt-loading.A role NaV1.7 in electrogenesis in DRG neurons is
well-established, and it is clear that NaV1.7 functions as
a threshold channel in these neurons, amplifying small
depolarizing inputs to bring the cell to threshold for
action potential generation [26,27] and possibly facilitat-
ing invasion into, and/or transmitter release from, pre-
terminal axons within the spinal cord dorsal horn [1,28].
In contrast, a functional role of NaV1.7 within supraoptic
neurons is less well understood. Action potential bursts,
triggered by osmotic changes, lead to release of vaso-
pressin by supraoptic magnocellular neurons [19] and it
is known that tetrodotoxin-sensitive sodium channels
contribute to this bursting [20-22].
Supraoptic magnocellular neurons are known to be
highly dynamic. It is known that, in response to changes
in osmolality, the expression of peptides within these
cells changes, and they change in size [29]. In parallel, it
has been shown that in response to increased osmolarity
there are changes in deployment of sodium channels,
with up-regulated expression of the NaV1.2 and NaV1.6
alpha subunits, and of the sodium channel beta-1 and
beta-2 subunits [24,25]. The present results show that
the level of NaV1.7 protein, like that of NaV1.2 and
NaV1.6 [24,25], is dynamic, and is up-regulated within
supraoptic magnocellular neurons exposed to osmotic
stress via salt-loading. A previous study [24] demon-
strated an increase in the amplitude of the transient Na+
current, and an even greater increase in the amplitude
and density of the Na+ currents evoked by slow ramp
stimuli in supraoptic neurons following salt-loading.
While definitive identification of the current as NaV1.7
current would require specific blockade or knockout, both
of these types of current have been observed to be pro-
duced by NaV1.7 [26]. Because NaV1.7 is present within
vasopressin neurons, it seems likely that this sodium chan-
nel isoform plays some role in vasopressin release in
response to the osmotic stress imposed by salt-loading.
Although only low levels of NaV1.7 have been reported
in the hypothalamus in primates [13], it is possible that
the density of NaV1.7 channels within magnocellular
neurons of the human supraoptic nucleus, like that in
rodents, is subject to up-regulation in response to some
forms of stress. NaV1.7 blockers are currently under
development as potential pharmacotherapeutics for
pain [30-34]. Hypothalamic dysfunction has not been
observed thus far in families with channelopathy-
associated insensitivity to pain due to null mutations in
the gene encoding NaV1.7. However, functional NaV1.7
channels are absent beginning in early embryogenesis in
affected individuals in these families, and the possibility
that there might be compensatory changes in hypothal-
amic neurons which maintain relatively normal function
in these cells cannot be excluded. Whether levels of
NaV1.7 are increased in response to environmental
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whether NaV1.7 plays a functional role in hypothalamic
neurons in humans, is not known. Until these questions
are resolved, the present findings suggest the need for
assessment of hypothalamic function in patients carrying
NaV1.7 mutations especially when subjected to stress,
and for monitoring of hypothalamic function as NaV1.7
blocking agents are studied.
Conclusions
In summary, our results demonstrate that sodium chan-
nel NaV1.7 is expressed in vasopressin-producing and
oxytocin-producing magnocellular neurosecretory neu-
rons of the rat hypothalamic supraoptic nucleus. The
level of NaV1.7 immunoreactivity in the supraoptic
nucleus is significantly increased following salt-loading,
suggesting a contribution of NaV1.7 in the response of
magnocellular neurosecretory neurons to osmotic stress.
While it is not yet known whether levels of expression
of NaV1.7 are increased in response to environmental
factors or stress within the human hypothalamus, or
whether NaV1.7 plays a functional role in hypothalamic
neurons in humans, the present findings suggest the
need for assessment of hypothalamic function in patients
carrying NaV1.7 mutations, especially when subjected to
stress, and for monitoring of hypothalamic function as
NaV1.7 blocking agents are studied.
Methods
Salt loading
Adult male Sprague-Dawley rats (200-220 g), housed
under a 12 h-12 h dark-light cycle, were salt-loaded with
2% NaCl (ad libitum) in their drinking water and unlim-
ited access to food. Rats were sacrificed for immuno-
cytochemical investigation 7 days following salt loading.
All experiments were approved by the VA Connecticut
Healthcare System Institutional Animal Care and Use
Committee. To confirm the extent of salt loading,
plasma osmotic pressure of the rats was measured
(vapor pressure osmometer model 5500, Wescor, USA).
Body weights were significantly (p < .05) lower in salt-
loaded (186.6 ± 4.7 g) compared to control (248.6 ± 1.9)
rats. Six control and 6 salt-loaded rats were used for the
immunocytochemistry studies.
Immunocytochemistry
Rats were perfused with 4% paraformaldehyde in 0.14 M
Sorensen’s phosphate buffer, pH 7.4, and the brain re-
moved and postfixed for 25-30 minutes. After cryopro-
tection in 30% sucrose in 0.01 M PBS for 24 h, the
brains were blocked, frozen and coronal cryosections
(16 μm) containing SON and optic chiasm were cut.
Sections were incubated in blocking solution (PBS
containing 3% normal donkey serum, 3% fish skingelatin, 0.1% Triton X-100 and 0.02% sodium azide) for
15 min at room temperature, primary antibody(ies)
[rabbit anti- NaV1.7, 1:200, Y083 (Black et al. 2012);
guinea pig anti-vasopressin, 1:100, Peninsula Lab, San
Carlos, CA); mouse anti-oxytocin, 1:500, Abcam,
Cambridge, MA)] in blocking solution 2-4 days at 4°C,
rinsed in PBS, incubated 1-2 days at 4°C with secondary
antibody(ies) [donkey anti-rabbit Alexa Fluor-488-con-
gugated F(ab’)2 fragment, donkey anti-rabbit Alexa
Fluor-Cy3, donkey anti-guinea pig Alexa Fluor-488; don-
key anti-mouse Alexa Fluor-488; all secondary anti-
bodies from Jackson Immuno Research, West Grove,
PA], rinsed with PBS and mounted on glass slides with
Aqua-polymount (Polyscience, Warrington, PA). Control
experiments in which the primary antibody was omitted
exhibited only background levels of labeling.
Quantification
Tissue sections were examined with a Nikon C1 confocal
microscope (Nikon USA, Melville, NY), using a 20× ob-
jective and operating in single mode for detection of
NaV1.7 alone or in frame lamba (sequential) mode for de-
tection of NaV1.7 and vasopressin or oxytocin to prevent
possible bleed-through between 488 and Cy3 channels.
For detection of NaV1.7 in the supraoptic nucleus
(SON), images were acquired from 6 control and 6 salt-
loaded rats, utilizing the same confocal settings for acqui-
sition of NaV1.7 immunofluorescent signals. Images were
opened in Nikon Elements and the mean signal intensity
of the circumscribed SON was calculated by the software.
For co-localization of NaV1.7 and vasopressin or oxyto-
cin in SON neurons, signals for NaV1.7 and vasopressin
were thresholded at intensities 20% above background
levels, and the percentage of vasopressin neurons express-
ing NaV1.7 was calculated. Data are presented as mean ±
SEM and statistical analysis was performed with Excel
Student’s t-test, with p < 0.05 considered significant.
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